Pfizer (PFE)

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15...

Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction.

Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued.

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.

The stock's yield is more than six times the S&P 500 average.

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev...

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

There is more to this stock than meets the eye.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 11% to $14.29, while non-GAAP net income reached $1.5 billion. Chief

Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center owner to raise elements of its full-year outlook. Chief Executive Officer Lisa Palmer said the company

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included patients aged 12 years and older, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50 and 100 milligram doses of LITFULO delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index, or VASI. Based on these results, Pfizer intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy for NSV for adults.

SPONSORED CONTENT -- (StatePoint) Pneumococcal pneumonia is a potentially serious illness caused by bacteria called pneumococcus. The illness can disrupt a person’s life for weeks, and when severe, can result in hospitalization. In fact, an estimated 225,000 adults are hospitalized with pneumococcal pneumonia each year in the United States.

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season. The ETF stated that “the evidence suggests that targeting XFG would provide the best protection against COVID-19.”1

AbbVie still looks like a compelling buy at its all-time high.

According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Could it become as successful in this niche as it was in the coronavirus vaccine market?